Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations

Virology Journal

Nora-Athina Viniou¹  George Vayopoulos¹  John Meletis¹  George Tzeletas¹  Efthymia Bazanis¹  Olga Benopoulou¹  Maria Michael¹  Panagiotis T Diamantopoulos¹ 

[1] 1st Department of Internal Medicine, Haematology Unit, National and Kapodistrian University of Athens, "Laikon" General Hospital, Athens 11527, Greece

关键词: autoimmunity;    Leukocytoclastic vasculitis;    RAEB-1;    Myelodysplastic syndrome;    5-azacytidine;    HTLV-1;   

Others  :  1155330
DOI  :  10.1186/1743-422X-9-1

 received in 2011-08-26, accepted in 2012-01-03,  发布年份 2012

【 摘 要 】

Myelodysplastic syndromes (MDS) are often accompanied by autoimmune phenomena. The underlying mechanisms for these associations remain uncertain, although T cell activation seems to be important. Human T-lymphotropic virus (HTLV-1) has been detected in patients with myelodysplastic syndromes, mostly in regions of the world which are endemic for the virus, and where association of HTLV-1 with rheumatological manifestation is not rare. We present here the case of a 58 year old man who presented with cytopenias, leukocytoclastic vasculitis of the skin and glomerulopathy, and was diagnosed as MDS (refractory anemia with excess blasts - RAEB 1). The patient also tested positive for HTLV-1 by PCR. After 8 monthly cycles of 5-azacytidine he achieved a complete hematologic remission. Following treatment, a second PCR for HTLV-1 was carried out and found to be negative. This is the first report in the literature of a HTLV-1-positive MDS with severe autoimmune manifestations, which was treated with the hypomethylating factor 5-azacitidine, achieving cytogenetic remission with concomitant resolution of the autoimmune manifestations, as well as HTLV-1-PCR negativity. HTLV-1-PCR negativity may be due to either immune mediated clearance of the virus, or a potential antiretroviral effect of 5-azacytidine. 5-azacytidine is known for its antiretroviral effects, although there is no proof of its activity against HTLV-1 infection in vivo.

【 授权许可】

   
2011 Diamantopoulos et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Vassilopoulos D, Calabrese LH: Rheumatologic manifestations of HIV-1 and HTLV-1 infections. Cleve Clin J Med 1998, 65(9):436-41.
• [2]Deguchi HE, Amemiya T: Two cases of uveitis with tubulointerstitial nephritis in HTLV-1 carriers. Jpn J Ophthalmol 2003, 47(4):372-8.
• [3]Miyanaga M, Shimizu K, Kawaguchi T, Miyata K, Mochizuki M: A clinical survey of uveitis in HTLV-1 endemic region. Ocul Immunol Inflamm 2009, 17(5):335-41.
• [4]Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Eds): WHO Classification of tumours of Haematopoietic and Lymphoid tissues Fourth edition. Lyon: IARC Press; 2008.
• [5]Hamblin T: Immunologic abnormalities in myelodysplastic syndromes. Hematol Oncol Clin North Am 1992, 6(3):571-86.
• [6]Williamson PJ, Oscier DG, Bell AJ, Hamblin TJ: Red cell aplasia in myelodysplastic syndrome. J Clin Pathol 1991, 44(5):431-2.
• [7]Das M, Chhabra R, Hinton SW: Cutaneous leukocytoclastic vasculitis and myelodysplastic syndrome with little or no evidence of associated autoimmune disorders-a case report and a brief review of the literature. Am J Med Sci 2008, 336(4):368-71.
• [8]Coha B, Fustar-Preradovic L, Sekelj S, Sekelj A: Total hearing loss and blindness caused by relapsing polychondritis and myelodysplastic syndrome. Eur Arch Otorhinolaryngol 2007, 264(12):1517-9.
• [9]Bouali F, Berrah A, Si Ahmed-Bouali D, Harrieche F, Benhalima M, Hamladji RM, Arrada M: Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients). Rev Med Interne 2005, 26(10):777-83.
• [10]Hull DR, McMillan SA, Rea IM, Boyd N, McMullin MF: Antineutrophil cytoplasmic antibodies in myelodysplasia. Ulster Med J 1996, 65(1):55-7.
• [11]Mobeireek A, Al-Mohareb F, Al-Dayel F, Al-Gazlan S, Alabdely H, Khalid M: Obliterative bronchiolitis in a patient with myelodysplastic syndrome before bone marrow transplantation. Respir Med 2007, 101(2):359-62.
• [12]Lin JT, Wang WS, Yen CC, Chiou TJ, Liu JH, Hsiao LT, Yang MH, Chao TC, Tai CJ, Chen PM: Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: remission of refractory anemia following mycophenolate mofetil. Ann Hematol 2002, 81(12):723-6.
• [13]George JN: Idiopathic thrombocytopenic purpura and myelodysplastic syndrome: distinct entities or overlapping syndromes? Leuk res 2002, 26(9):789-90.
• [14]Kuroda J, Kimura S, Kobayashi Y, Wada K, Uoshima N, Yoshikawa T: Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura. Acta Haematol 2002, 108(3):139-43.
• [15]Williamson PJ, Oscier DG, Bell AJ, Hamblin TJ: Red cell aplasia in myelodysplastic syndrome. J Clin Pathol 1991, 44(5):431-2.
• [16]Tsuji G, Maekawa S, Saigo K, Nobuhara Y, Nakamura T, Kawano S, Koshiba M, Asahara S, Chinzei T, Kumagai S: Dermatomyositis and myelodysplastic syndrome with myelofibrosis responding to methotrexate therapy. Am J Hematol 2003, 74(3):175-8.
• [17]Enright H, Miller W: Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma 1997, 24(5-6):483-9.
• [18]Steurer M, Fritsche G, Tzankov A, Gotwald T, Sturm W, Konwalinka G, Gruber J: Large-vessel arteritis and myelodysplastic syndrome: report of two cases. Eur J Hematol 2004, 73(2):128-33.
• [19]Espinosa G, Font J, Muñoz-Rodríguez FJ, Cervera R, Ingelmo M: Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship? Clin Rheumatol 2002, 21(4):309-13.
• [20]Funato K, Kuriyama Y, Uchida Y, Suzuki A, Miyazawa K, Ohyashiki K: Myelodysplastic syndrome accompanied by Addison's disease and multiple autoimmune phenomena: steroid therapy resolved cytopenias and all immune disorders. Intern Med 2001, 40(10):1041-4.
• [21]Bogdanović R, Kuzmanović M, Marković-Lipkovski J, Ognjanović M, Mićić D, Stanković I, Stajić N, Nikolić V, Bunjevacki G: Glomerular involvement in myelodysplastic syndromes. Pediatr Nephrol 2001, 16(12):1053-7.
• [22]Doukkali O, Tarrass F, Medkouri G, Fatihi E, Ramdani B, Zaid D, Azzouzi S, Sqalli S: Extramembranous glomerulonephritis and myelodysplastic syndrome. Nephrologie 2004, 25(2):59-61.
• [23]Paydas S, Paydas S, Tuncer I, Zorludemir S, Gonlusen G: A case with membranous glomerulonephritis and myelodysplastic syndrome. Nephron 1992, 62(2):231-2.
• [24]Hayashi S, Okada T, Tsutsumi H, Kumakawa T, Mori M: A case of myelodysplastic syndrome associated with IgA nephropathy. Nippon Ronen Igakkai Zasshi 1999, 36(5):373-6.
• [25]Komatsuda A, Miura I, Ohtani H, Hamai K, Wakui H, Imai H, Kobayashi Y, Miura AB, Chubachi A: Crescentic glomerulonephritis accompanied by myeloperoxidase-antineutrophil cytoplasmic antibodies in a patient having myelodysplastic syndrome with trisomy 7. Am J Kidney Dis 1998, 31(2):336-40.
• [26]Barrett AJ, Sloand E: Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 2009, 94(4):449-51.
• [27]Kotsianidis I, Bouchliou I, Nakou E, Spanoudakis E, Margaritis D, Christophoridou AV, Anastasiades A, Tsigalou C, Bourikas G, Karadimitris A, Tsatalas C: Kinetics, function and bone marrow trafficking of CD4 + CD25 + FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009, 23(3):510-8.
• [28]Shimamoto T, Ohyashiki K: Immunosuppressive treatments for myelodysplastic syndromes. Leuk Lymphoma 2003, 44(4):593-604.
• [29]Barrett AJ, Sloand EM: Immunosuppressive therapy for myelodysplastic syndromes: refining the indications. Curr Hematol Malig Rep 2008, 3(1):23-8.
• [30]Politis C, Kavallierou L, Georgakopoulou E, Gounari F, Zervou E, Spiliotopoulou I, Christaki E, Kalitzeris I, Farmaki K, Zacharaki P, Marantidou O, Ganochoritis A, Koukakis N, Hatzidimitriou G, Economopoulou C: The prevalence of anti-HTLV-I-II in blood donors in Greece. Arch Hell Med 1999, 16(5):480-487.
• [31]Inoue H, Matsushita K, Arima N, Hamada H, Uozumi K, Ozaki A, Akimoto M, Kawada H, Kukita T, Yoshimitsu M, Matsumoto T, Tei C: High prevalence of human T-lymphotropic virus type I carriers among patients with myelodysplastic syndrome refractory anemia with excess of blasts (RAEB), RAEB in transformation and acute promyelocytic leukemia. Leuk Lymphoma 2008, 49(2):315-21.
• [32]Karlic H, Möstl M, Mucke H, Pavlova B, Pfeilstöcker M, Heinz R: Association of human T-cell leukemia virus and myelodysplastic syndrome in a central European population. Cancer Res 1997, 57(21):4718-21.
• [33]Matsushita K, Ozaki A, Arima N, Tei C: Human T-lymphotropic virus type I infection and idiopathic thrombocytopnic purpura. Hematology 2005, 10(2):95-9.
• [34]Watanabe T, Mochizuki M, Yamaguchi K: HTLV-1 uveitis (HU). Leukemia 1997, 11:582-4.
• [35]Deguchi HE, Amemiya T: Two cases of uveitis with tubulointerstitial nephritis in HTLV-1 carriers. Jpn J Ophtalmol 2003, 47(4):372-8.
• [36]Masuko-Hongo K, Nishioka K: HTLV-I associated arthropathy (HAAP)--a review. Ryoikibetsu shokogun shirizu 2000, (32):525-7.
• [37]Hida A, Imaizumi M, Sera N, Akahoshi M, Soda M, Maeda R, Nakashima E, Nakamura H, Ida H, Kawakami A, Eguchi K: Association of human T lymphotropic virus type I with Sjogren syndrome. Ann Rheum Dis 2010, 69(11):2056-7.
• [38]Matsuyama W, Kawabata M, Mizoguchi A, Iwami F, Wakimoto J, Osame M: Influence of human T lymphotrophic virus type I on cryptogenic fibrosing alveolitis - HTLV-I associated fibrosing alveolitis: proposal of a new clinical entity. Clin Exp immunol 2003, 133(3):397-403.
• [39]Caldwell CJ, Barrett WY, Breuer J, Farmer SF, Swash M: HTLV-1 polymyositis. Neuromuscul Disord. 1996, 6(3):151-4.
• [40]Cruz BA, Catalan-Soares B, Proietti F: Higher prevalence of fibromyalgia in patients infected with human T cell lymphotropic virus type I. J Rheumatol 2006, 33(11):2300-3.
• [41]Miller ME, Shah DJ, Barton EN, Gray AH, Yeates CB: Human T-cell lymphotropic virus-1-associated renal disease in Jamaican children. Pediatr Nephrol 2001, 16(1):51-6.
• [42]Namie S, Shimamine R, Ichinose H, Nishikawa Y, Ideguchi M, Ozono Y, Harada T, Hara K: Evaluation of anti-HTLV-1 antibody in primary glomerulonephritis. J Int Med Res 1995, 23(1):56-60.
• [43]Machuca A, Rodes B, Soriano V: The effect of antiretroviral therapy on HTLV infection. Virus Res 2001, 78(1-2):93-100.
• [44]Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, Rezaee SA, Yazdi MT, Shirdel A, de Thé H, Hermine O, Farid R, Bazarbachi A: Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113(26):6528-32.
• [45]Garcia-Lerma JG, Nidtha S, Heneine W: Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine. J Inf Dis 2001, 184(4):507-10.
• [46]Lavelle D, Saunthararajah Y, Desimone J: DNA methylation and mechanism of action of 5-azacytidine. Blood 2008, 111(4):2485.
• [47]Müller CI, Rüter B, Koeffler HP, Lübbert M: DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Curr Pharm Biotechnol 2006, 7(5):315-21.
• [48]Sato H, Oka T, Shinnou Y, Kondo T, Washio K, Takano M, Takata K, Morito T, Huang X, Tamura M, Kitamura Y, Ohara N, Ouchida M, Ohshima K, Shimizu K, Tanimoto M, Takahashi K, Matsuoka M, Utsunomiya A, Yoshino T: Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am J Pathol 2010, 176(1):402-15.
• [49]Dapp MJ, Clouser CL, Patterson S, Mansky LM: 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J Virol 2009, 83(22):11950-8.
• [50]Saggioro D, Panozzo M, Chieco-Bianchi L: Human T-lymphotropic virus type I transcriptional regulation by methylation. Cancer Res 1990, 50(16):4968-73.
• [51]Clouser CL, Patterson SE, Mansky LM: Exploiting drug repositioning for discovery of a novel HIV combination therapy. J Virol 2010, 84(18):9301-9.
• [52]Uenogawa K, Hatta Y, Arima N, Hayakawa S, Sawada U, Aizawa S, Yamamoto T, Takeuchi J: Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia/lymphoma. Int J Mol Med 2011, 28(5):835-9.